Umbilical cord blood transplantation in XXXX .

@entity1 @entity17454 @entity1200 @entity116
OBJECTIVE: To report the use of umbilical cord blood (UCB) stem cell transplantation in @entity17454 ( @entity17454 ) when a matched sibling donor was unavailable. METHODS: Three @entity1 with @entity17454 received unrelated umbilical cord blood stem cell transplantation after a preparative regimen for the treatment of @entity1200 . The @entity1 ranged in age from 1.9 to 7.9 years. The cord blood units were 4/6 HLA antigen matches in 2 @entity1 and 5/6 in 1 @entity1 , with molecular HLA-DR match in all 3 @entity1 . RESULTS: The time for neutrophil engraftment (ANC >500/mm(3)) was 11 to 16 days, and the average time for platelet engraftment was 36 to 49 days. One @entity1 had no evidence of GvHD, 1 @entity1 grade I, and 1 @entity1 grade II. No @entity1 had chronic GvHD. The @entity1 with grade II GvHD also had gut involvement. Immunologic reconstitution demonstrated that cord blood stem cell transplantation resulted in consistent and stable T-, B-, and NK-cell development. Functional B-cell antibody responses revealed that 2 of the @entity1 in whom IVIG has been discontinued had low detectable antibody responses to @entity116 and diphtheria toxoid immunizations at 18 to 24 months after transplantation. CONCLUSIONS: Unrelated umbilical donor cord blood is an alternative source of stem cells for transplantation in @entity1 with @entity17454 when a suitable HLA-matched donor is not available. Benefits of UCB include rapid and reliable recovery of immune function, low risk of GvHD, and low viral transmission rate.
